Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same

A technology of mannan peptides and vaccine adjuvants, which is applied to medical preparations containing active ingredients, antiviral agents, antibody medical components, etc., can solve problems such as no immune response, reduce the amount of antigen used, and induce cellular immunity Response, immune response enhancement effect

Inactive Publication Date: 2011-08-31
XI AN JIAOTONG UNIV
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, after being vaccinated against hepatitis B vaccine, about 15%-30% of adults have no immune response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same
  • Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same
  • Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 α-mannan peptide adjuvant H1N1 vaccine intramuscular injection and its immune effect detection

[0041] 1.1 Preparation of H1N1 vaccine intramuscular injection and control preparation

[0042] Vaccine solution: Take 40 μL of H1N1 split vaccine solution containing 420 μg / mL of HA, add it to 360 μL of water for injection, and dilute it 10 times to obtain 400 μL of vaccine dilution solution with a concentration of 0.042 μg / μL, which is recorded as drug solution ①. The H1N1 split vaccine was donated by Zhejiang Tianyuan Biological Products Co., Ltd.

[0043] α-mannan peptide solution: Take 15 mg of α-mannan peptide and dissolve it in 1 mL of water for injection to obtain 1 mL of adjuvant solution with a concentration of 15 mg / mL, which is recorded as liquid ②. α-Mannan peptide was purchased from Sinopharm Chuankang Pharmaceutical Co., Ltd.

[0044] The preparation of intramuscular injection of H1N1 vaccine with different proportions is shown in Table 1, in which...

Embodiment 2

[0078] Example 2. α-mannan peptide adjuvant H1N1 vaccine nasal drops and its immune effect detection

[0079] 2.1 Preparation of H1N1 vaccine nasal drops and control preparations

[0080] 1) Preparation of nasal drop adjuvant solution:

[0081] Sucrose 684mg, sodium glutamate 9.4mg, pig skin collagen 100mg, arginine 121mg, K 2 HPO 4 113mg, KH 2 PO 4 After mixing 48mg, add water to fully dissolve and add water to 5mL.

[0082] 2) Vaccine solution: Take 40 μL of vaccine solution containing 420 μg / mL of HA, add it to 360 μL of water for injection, and dilute by 10 times to obtain 400 μL of vaccine dilution solution with a concentration of 0.042 μg / μL.

[0083] 3) Adjuvant solution: 50 mg of α-mannan peptide was dissolved in 1 mL of water for injection to obtain 1 mL of adjuvant solution with a concentration of 50 mg / mL.

[0084] The preparation of intramuscular injection of H1N1 vaccine with different proportions is shown in Table 1, in which, 1-2 are the vaccine control g...

Embodiment 3

[0114] Example 3 Preparation of Intramuscular Injection of α-Mannan Peptide Adjuvant Seasonal Influenza Vaccine

[0115] Vaccine solution: Take 40 μL of the seasonal influenza trivalent vaccine solution, add it to 360 μL of water for injection, and dilute the amount by 10 times to obtain 400 μL of the vaccine dilution, which is recorded as the drug solution ①.

[0116] Adjuvant solution: Take 15 mg of α-mannan peptide and dissolve it in 1 mL of water for injection to obtain 1 mL of adjuvant solution with a concentration of 15 mg / mL, which is recorded as liquid ②.

[0117] The dosage formula of intramuscular injection of seasonal influenza vaccine is shown in Table 3:

[0118] Table 3 Preparation of intramuscular injection of seasonal influenza vaccine

[0119] group

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of alpha-mannatide as vaccine adjuvant. The alpha-mannatide which is taken as the vaccine adjuvant has the advantages of being safe, effective, stable and low in price. Firstly, the alpha-mannatide is taken as the immune reinforcing agent to be applied in the clinic, and the main dosage form of the alpha-mannatide is tablet, muscle injection and oral liquid. Therefore, the alpha-mannatide is proved to be safe abundantly, and the alpha-mannatide is safe and reliable within the range of the dosage for immune; secondly, the alpha-mannatide is from a microbe fermentation product, low in price, and good in economic benefit; importantly, the alpha-mannatide can be used for effectively reducing the dosage of the antigen required by the protective immunity; and the higher immunity reaction can be stimulated under the same dosage of the antigen, the cell immune response can be preferably induced particularly, and the alpha-mannatide is good in immune protective function compared with the aluminum adjuvant.

Description

technical field [0001] The patent of the present invention belongs to the technical field of vaccine preparations, and particularly relates to the application of α-mannan peptide as a vaccine adjuvant and the vaccine preparation prepared based on the application. Background technique [0002] An adjuvant refers to a substance that can be applied simultaneously or in advance with an antigen to enhance the body's immune response to the antigen or change the type of immune response. An ideal adjuvant should have the characteristics of effectiveness, safety, stability and economy. Currently, enhancing the immunogenicity of vaccines through adjuvants has become a key area of ​​vaccine development. The main advantage of adjuvanted vaccines is to reduce the amount of antigen required for protective immunity. This dose-saving effect helps increase the number of available vaccine doses, which is especially important during an infectious disease epidemic when drugmakers' supply capa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39A61K39/00A61K39/125A61K39/145A61K39/29A61P31/12A61P31/14A61P31/16
Inventor 王冰张卉冯素玲
Owner XI AN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com